FRES

AnPac Bio-Medical Science Co Ltd is a China-based biotechnology company focused on early cancer screening and detection. The Company markets and sells multi-cancer screening and detection test that uses cancer differentiation analysis (CDA), technology and its cancer-detection device or CDA device. In addition to early cancer screening and detection, its CDA technology assists physicians in cancer diagnosis, prognosis and recurrence. Its CDA technology provides a platform on which it has developed cancer screening and detection test using its CDA technology, or CDA test, and its CDA device. Its CDA technology focuses on biophysical properties in human blood. The Company have established two clinical laboratories in China and one clinical laboratory in the United States. The Company is also engaged in providing technical solution and outsourcing consulting service focusing on the digital, internet, and Web3 transformation of start-ups and traditional enterprises.